<DOC>
	<DOC>NCT01935167</DOC>
	<brief_summary>Phase 2 clinical study to evaluate of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy</brief_summary>
	<brief_title>To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy</brief_title>
	<detailed_description>A Phase Ⅱ, prospective, 24 weeks, double-blind, placebo-controlled, randomized, multi-center clinical trial for the evaluation of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Has confirmed diabetic mellitus prior to 6years Has confirmed microalbuminuria 30 ~ 299㎍/㎎creatinine prior to 5months one time and microalbuminuria 30 ~ 299㎍/㎎creatinine during screening period Blood Pressure(BP) ≤ 150 / 90 mmHg estimated glomerular filtration rate(eGFR) ≥ 30 ml/min/1.73m2 Hemoglobin A1c(HbA1c) ≤ 9% Low density lipoprotein(LDLC) ≤ 130mg/dl kidney or liver disease as follows i.Serum Creatinine &gt; 2.0mg/dl ii.Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 2 x Upper Limit Normal(ULN) iii.Total Bilirubin &gt; 2 x ULN Organic gastrointestinal disorder or Chronic gastroenterologic disorders prior to 6 months as follows [NOTE] Active Crohn's disease, Active ulcerative colitis, Chronic peptic ulcer disease, etc. cardiovascular disease prior to 3 months as follows [NOTE] Unstable angina pectoris, Myocardial infarction, Coronary artery bypass surgery, Percutaneous Transluminal Coronary Angioplasty, transient ischemic attack, cerebrovascular accident etc.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Microalbuminuria</keyword>
</DOC>